

Company Number: 285181

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

Directors' Report and Financial Statements

for the year ended 31 December 2016

O'Gorman Brannigan Purtill & Co. Limited
Certified Public Accounts and registered Auditors
22 Bridge Street,
Ringsend,
Dublin 4
Ireland

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

CONTENTS

	Page
Directors and Other Information	3
Directors' Report	4 - 5
Directors' Responsibilities Statement	6
Independent Auditor's Report	7
Income Statement	8
Statement of Financial Position	9
Statement of Changes in Equity	10
Statement of Cash Flows	11
Notes to the Financial Statements	12 - 15
Supplementary Information on Income and Expenditure Account	17
Supplementary Information on Income Statement by Cost Centre	18 - 32

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

DIRECTORS AND OTHER INFORMATION

Directors

Rosie McGlone
Maria Finn
Margaret Devlin
Frank Kennifick
Donal Walshe
Noreen Byrne
Doreen Carpenter
David Lynch
Ann Corrigan
Kathy White
Ray McGrath
Vincent Jackson
Mark Ward (Appointed 8 July 2016)

Company Secretary

Sandra Mullen

Company Number

285181

Business Address

Unit A1,
Weatherwell Business Park,
Clondalkin,
Dublin 22.

Auditors

O'Gorman Brannigan Purtill & Co. Limited
Certified Public Accounts and registered Auditors
22 Bridge Street,
Ringsend,
Dublin 4
Ireland

Bankers

Permanent TSB
Liffey Valley SC
Quarryvale
Dublin 22

Solicitors

Oliver Burke
Omac Business Centre
Nangor Road
Clondalkin
Dublin 22

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

DIRECTORS' REPORT

for the year ended 31 December 2016

The directors present their report and the audited financial statements for the year ended 31 December 2016.

Principal Activity

The principal activity during the year was the design and implementation of an integrated strategy to address the context and consequences of problem drug and alcohol abuse.

The Company is limited by guarantee not having a share capital.

There has been no significant changes in these activities during the year ended 31st December 2015.

The Company is limited by guarantee not having a share capital.

Principal Risks and Uncertainties

Clondalkin Drug and Alcohol Task Force Project Management Limited is mainly dependent on income provided from government and semi - state funders. As with similar government funded companies, the company is affected by both budgetary constraints implemented by the government and by external economic restraints. The directors has assessed the risks and have taken measures to manage these risks.

The company faces increasing material and energy costs. The directors are of the opinion that the company is well positioned to manage these costs. The company operates in a cyclical industry and is affected by factors beyond the control the company.

Financial Results

The deficit for the year after providing for depreciation amounted to €(6,675) (2015 - €(14,553)).

At the end of the year the company has assets of €47,277 (2015 - €76,056) and liabilities of €15,715 (2015 - €37,819). The net assets of the company have decreased by €(6,675).

Directors and Secretary

The directors who served throughout the year, except as noted, were as follows:

Rosie McGlone
Maria Finn
Margaret Devlin
Frank Kennifick
Donal Walshe
Noreen Byrne
Doreen Carpenter
David Lynch
Ann Corrigan
Kathy White
Ray McGrath
Vincent Jackson
Mark Ward (Appointed 8 July 2016)

The secretary who served throughout the year was Sandra Mullen

There were no changes in shareholdings between 31 December 2016 and the date of signing the financial statements.

In accordance with the Articles of Association, the directors retire by rotation and, being eligible, offer themselves for re-election.

Future Developments

The company plans to continue its present activities and current trading levels. Employees are kept as fully informed as practicable about developments within the business.

Post Statement of Financial Position Events

There have been no significant events affecting the company since the year-end.

Auditors

The auditors, O'Gorman Brannigan Purtill & Co. Limited, (Certified Public Accounts and registered Auditors) have indicated their willingness to continue in office in accordance with the provisions of Section 383(2) of the Companies Act, 2014.

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

DIRECTORS' REPORT

for the year ended 31 December 2016

Accounting Records

To ensure that adequate accounting records are kept in accordance with Sections 281 to 285 of the Companies Act 2014, the directors have employed appropriately qualified accounting personnel and have maintained appropriate computerised accounting systems. The accounting records are located at the company's office at .

Signed on behalf of the board

Director

Date:

11/5/17

Aileen Byrne

Date:

14/5/17

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

DIRECTORS' RESPONSIBILITIES STATEMENT

for the year ended 31 December 2016

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently.
- make judgements and estimates that are reasonable and prudent.
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy and enable them to ensure that the financial statements and directors' report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the directors are aware:


- there is no relevant audit information (information needed by the company's auditor in connection with preparing the auditor's report) of which the company's auditor is unaware, and
- the directors have taken all the steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information.

Signed on behalf of the board



Director

Date: 11/5/17



Date: 11/5/17

INDEPENDENT AUDITOR'S REPORT

to the Members of Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

We have audited the financial statements of Clondalkin Drug and Alcohol Task Force Project Management CLG for the year ended 31 December 2016 which comprise the Income Statement, the Statement of Financial Position, the Statement of Changes in Equity, the Statement of Cash Flows, the Accounting Policies and the related notes. The relevant financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

This report is made solely to the company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditors

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and otherwise comply with the Companies Act 2014. Our responsibility is to audit and express an opinion on the financial statements in accordance with Irish law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practice Board's Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the directors; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Directors' Report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

Opinion on financial statements

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2016 and of its results for the year then ended; and
- have been properly prepared in accordance with the relevant financial reporting framework and, in particular, the requirements of the Companies Act 2014.

Matters on which we are required to report by the Companies Act 2014.

- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.
- In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited.
- The financial statements are in agreement with the accounting records.
- In our opinion the information given in the Directors' Report is consistent with the financial statements.

Matters on which we are required to report by exception

We have nothing to report in respect of the provisions in the Companies Act 2014 which require us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions specified by Sections 305 to 312 of the Act are not made.



John O'Gorman

for and on behalf of
O'GORMAN BRANNIGAN PURTILL & CO. LIMITED
Certified Public Accounts and registered Auditors
22 Bridge Street,
Ringsend,
Dublin 4
Ireland

Date: 11/5/17

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)


INCOME STATEMENT


for the year ended 31 December 2016

	Notes	2016 €	2015 €
Income	5	340,968	374,817
Expenditure		(347,643)	(389,370)
Total Comprehensive Income		<u>(6,675)</u>	<u>(14,553)</u>

The company has no recognised gains or losses other than the results for the year. The results for the year have been calculated on the historical cost basis. The company's income and expenses all relate to continuing operations.

Approved by the board on 11/5/17 and signed on its behalf by:


11/5/17



Clondalkin Drug and Alcohol Task Force Project Management CLG


(A company limited by guarantee, without a share capital)

STATEMENT OF FINANCIAL POSITION

as at 31 December 2016

	Notes	2016 €	2015 €
Non-Current Assets			
Tangible assets	8	1,212	2,425
Current Assets			
Cash and cash equivalents		46,065	73,631
Creditors: Amounts falling due within one year	9	(15,715)	(37,819)
Net Current Assets		30,350	35,812
Total Assets less Current Liabilities		31,562	38,237
Reserves			
Restricted Funds		31,562	38,237
Members' Funds		31,562	38,237

Approved by the board on 11/5/17 and signed on its behalf by:



Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

STATEMENT OF CHANGES IN EQUITY

as at 31 December 2016

	Retained surplus	Total
	€	€
At 1 January 2015	52,790	52,790
Deficit for the year	(14,553)	(14,553)
At 31 December 2015	38,237	38,237
Deficit for the year	(6,675)	(6,675)
At 31 December 2016	31,562	31,562

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

STATEMENT OF CASH FLOWS

for the year ended 31 December 2016

	Notes	2016 €	2015 €
Cash flows from operating activities			
Deficit for the year		(6,675)	(14,553)
Adjustments for:			
Depreciation		1,213	1,213
		<u>(5,462)</u>	<u>(13,340)</u>
Movements in working capital:			
Movement in debtors		-	3,125
Movement in creditors		(22,104)	28,925
		<u>(27,566)</u>	<u>18,710</u>
Cash (used in)/generated from operations			
		<u>(27,566)</u>	<u>18,710</u>
Net (decrease)/increase in cash and cash equivalents		(27,566)	18,710
Cash and cash equivalents at beginning of financial year		73,631	54,921
		<u>73,631</u>	<u>54,921</u>
Cash and cash equivalents at end of financial year	13	<u>46,065</u>	<u>73,631</u>

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2016

1. GENERAL INFORMATION

Clondalkin Drug and Alcohol Task Force Project Management CLG is a company limited by guarantee incorporated in the Republic of Ireland.

2. ACCOUNTING POLICIES

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 December 2016 have been prepared in accordance with generally accepted accounting principles in Ireland and Irish statute comprising the Companies Act 2014 and in accordance with the Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland (FRS 102) issued by the Financial Reporting Council. There have been no transitional adjustments made.

Basis of preparation

The financial statements have been prepared in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

Income

Income comprises grants received by various government bodies.

Property, plant and equipment and depreciation

Property, plant and equipment are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of property, plant and equipment, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	- 15% Straight line
----------------------------------	---------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation

The company is exempt from taxation due to its company status.

3. ADOPTION OF FRS 102

This is the first set of financial statements prepared by Clondalkin Drug and Alcohol Task Force Project Management CLG in accordance with accounting standards issued by the Financial Reporting Council, including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"). The company transitioned from previously extant Irish and UK GAAP to FRS 102 as at 1 January 2014.

4. DEPARTURE FROM COMPANIES ACT 2014 PRESENTATION

The directors have elected to present an Income and Expenditure Account instead of a Profit and Loss Account in these financial statements as this company is a not-for-profit entity.

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2016

continued

5. INCOME

The income for the year has been derived from:-

	2016 €	2015 €
HSE Income	202,871	202,871
T&R Reallocation	-	4,000
Pobal Income	-	30,139
CL 2-9 Reallocation	-	10
Education & Training Income	138,097	137,797
	<u>340,968</u>	<u>374,817</u>

The whole of the company's income is attributable to its market in the Republic of Ireland and is derived from the principal activity of the design and implementation of an integrated strategy to address the context and consequences of problem drug and alcohol abuse.

STATE FUNDING (per Department of Finance circular 13/2014)

FUNDER	PROGRAMME	TERM	FUND TAKEN TO INCOME IN PERIOD	CASH RECEIVED IN THE PERIOD	CAPITAL GRANT	FUND DUE AT PERIOD END	FLOAT FUNDING IN PLACE	PURPOSE OF FUND
EDUCATION AND TRAINING BOARD	CLONDALKIN PREVENTION PROJECT	12 MTHS	€138,097	€138,097	NIL	NIL	NIL	SERVICE DELIVERY
HEATH SERVICE EXECUTIVE	DRUGS EDUCATION	12 MTHS	€202,871	€202,871	NIL	NIL	NIL	SERVICE DELIVERY

Restriction on use : Funds may only be used for the purpose of the programme.

6. OPERATING DEFICIT

	2016 €	2015 €
Operating deficit is stated after charging:		
Depreciation of property, plant and equipment	1,213	1,213
	<u>1,213</u>	<u>1,213</u>

7. EMPLOYEES AND REMUNERATION

Number of employees

The average number of persons employed (including executive directors) during the year was as follows:

	2016 Number	2015 Number
Administration	7	7

The staff costs comprise:

	2016 €	2015 €
Wages and salaries	221,069	218,420
Social welfare costs	22,981	22,761
	<u>244,050</u>	<u>241,181</u>

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2016

continued

SALARY BANDS

TOTAL EMPLOYEE BENEFITS SALARY BAND	NO. OF EMPLOYEES
€60,000 - €70,000	NIL
€70,000 - €79,999	NIL
€80,000 - €89,999	NIL
€90,000 - €99,999	NIL

8. PROPERTY, PLANT AND EQUIPMENT

	Fixtures, fittings and equipment €	Total €
Cost or Valuation		
At 31 December 2016	40,143	40,143
Depreciation		
At 1 January 2016	37,718	37,718
Charge for the year	1,213	1,213
At 31 December 2016	38,931	38,931
Net book value		
At 31 December 2016	1,212	1,212
At 31 December 2015	2,425	2,425

8.1. PROPERTY, PLANT AND EQUIPMENT PRIOR YEAR

	Fixtures, fittings and equipment €	Total €
Cost or Valuation		
At 31 December 2015	40,143	40,143
Depreciation		
At 1 January 2015	36,505	36,505
Charge for the year	1,213	1,213
At 31 December 2015	37,718	37,718
Net book value		
At 31 December 2015	2,425	2,425
At 31 December 2014	3,638	3,638

9. CREDITORS

Amounts falling due within one year

	2016 €	2015 €
Other creditors	4,592	34,757
Accruals	11,123	3,062
	15,715	37,819

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

NOTES TO THE FINANCIAL STATEMENTS

continued

for the year ended 31 December 2016

10. STATUS

The liability of the members is limited.

Every member of the company undertakes to contribute to the assets of the company in the event of its being wound up while they are members, or within one year thereafter, for the payment of the debts and liabilities of the company contracted before they ceased to be members, and of the costs, charges and expenses of winding up, and for the adjustment of the rights of the contributors among themselves, such amount as may be required, not exceeding € 2.

11. CAPITAL COMMITMENTS

The company had no material capital commitments at the year-ended 31 December 2016.

12. EVENTS AFTER END OF REPORTING PERIOD

There have been no significant events affecting the company since the year-end.

13. CASH AND CASH EQUIVALENTS

	2016 €	2015 €
Cash and bank balances	10,533	38,801
Cash equivalents	35,532	34,830
	<u>46,065</u>	<u>73,631</u>

14. TAX CLEARANCE

This company has a tax clearance certificate.

15. APPROVAL OF FINANCIAL STATEMENTS

The financial statements were approved and authorised for issue by the board of directors on 11-6-17.

CLONDALKIN DRUG AND ALCOHOL TASK FORCE PROJECT MANAGEMENT CLG
(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION

RELATING TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2016

NOT COVERED BY THE REPORT OF THE AUDITORS

THE FOLLOWING PAGES DO NOT FORM PART OF THE AUDITED FINANCIAL STATEMENTS

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

DETAILED INCOME AND EXPENDITURE ACCOUNT

for the year ended 31 December 2016

	2016 €	2015 €
Income		
HSE Income	202,871	202,871
Treatment & Rehab Transfer	-	4,000
Pobal Income	-	30,139
CL 2-9 Reallocation	-	10
Education and Training Income	138,097	137,797
	<u>340,968</u>	<u>374,817</u>
Expenditure		
Programme Costs	40,503	65,888
Training	1,600	-
Facilitation	3,603	875
Research	19,547	9,906
Wages and salaries	221,069	218,420
Social welfare costs	22,981	22,761
Supervision	-	2,791
Rent payable	11,135	10,369
Light and heat	1,644	2,042
Research Reallocation	-	4,000
Repairs and maintenance	1,921	1,767
[Printing, postage and stationery	4,202	4,413
Advertising	5,964	1,445
Telephone	2,960	3,402
Computer costs	2,949	789
Main Reallocation	-	10
Travelling and Subsistence	844	2,082
Bank charges	80	168
2016 Deferred Expenditure	-	30,139
General expenses	2,305	4,090
Auditor's remuneration	3,123	2,800
Depreciation	1,213	1,213
	<u>347,643</u>	<u>389,370</u>
Net deficit	<u>(6,675)</u>	<u>(14,553)</u>

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

INCOME STATEMENT

for the year ended 31 December 2016

Research

	Notes	2016 €	2015 €
Income		-	4,000
Expenditure		(8,084)	(9,916)
Deficit for the year		<u>(8,084)</u>	<u>(5,916)</u>

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

DETAILED INCOME AND EXPENDITURE ACCOUNT

for the year ended 31 December 2016

Research

	2016 €	2015 €
Income		
Treatment & Rehab Transfer	-	4,000
	<u>-</u>	<u>4,000</u>
Expenditure		
Programme Costs	2,040	-
Research	840	9,906
Advertising	5,036	-
Bank charges	-	10
General expenses	168	-
	<u>8,084</u>	<u>9,916</u>
Net deficit	<u>(8,084)</u>	<u>(5,916)</u>

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

INCOME STATEMENT

for the year ended 31 December 2016

Community Training & Drugs Education

	Notes	2016 €	2015 €
Surplus for the year		-	-

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

INCOME STATEMENT

for the year ended 31 December 2016

Co - Ordination Account

	Notes	2016 €	2015 €
Income		88,583	88,583
Expenditure		(88,541)	(88,666)
Surplus/(deficit) for the year		<u>42</u>	<u>(83)</u>

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS**DETAILED INCOME AND EXPENDITURE ACCOUNT**

for the year ended 31 December 2016

Co - Ordination Account

	2016 €	2015 €
Income		
HSE Income	88,583	88,583
	<u>88,583</u>	<u>88,583</u>
Expenditure		
Programme Costs	1,000	-
Training	1,200	-
[Facilitation	1,392	550
Research	6,988	-
Wages and salaries	70,220	75,309
Social welfare costs	6,830	7,440
Supervision	-	1,861
Rent payable	911	2,646
Repairs and maintenance	-	221
Advertising	-	513
General expenses	-	126
	<u>88,541</u>	<u>88,666</u>
Net surplus/(deficit)	<u>42</u>	<u>(83)</u>

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

INCOME STATEMENT

for the year ended 31 December 2016

Admin Account Project

	Notes	2016 €	2015 €
Expenditure		(1,213)	(9,613)
Deficit for the year		<u>(1,213)</u>	<u>(9,613)</u>

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS**DETAILED INCOME AND EXPENDITURE ACCOUNT**

for the year ended 31 December 2016

Admin Account Project

	2016 €	2015 €
	<u>-</u>	<u>-</u>
Expenditure		
Programme Costs	-	8,400
Depreciation	<u>1,213</u>	<u>1,213</u>
	<u>1,213</u>	<u>9,613</u>
Net deficit	<u>(1,213)</u>	<u>(9,613)</u>

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

INCOME STATEMENT

for the year ended 31 December 2016

Treatment & Rehab

	Notes	2016 €	2015 €
Income		114,288	114,288
Expenditure		(111,992)	(112,643)
Surplus for the year		<u>2,296</u>	<u>1,645</u>

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

DETAILED INCOME AND EXPENDITURE ACCOUNT

for the year ended 31 December 2016

Treatment & Rehab

	2016 €	2015 €
Income		
HSE Income	114,288	114,288
	<u>114,288</u>	<u>114,288</u>
Expenditure		
Programme Costs (Note 1)	30,552	43,022
Facilitation	711	400
Research (Note 2)	11,719	-
Wages and salaries	48,726	45,153
Social welfare costs	5,172	4,791
Rent payable	5,112	2,500
Light and heat	819	1,452
Research Reallocation	-	4,000
Repairs and maintenance	875	836
Printing, postage and stationery	1,923	2,251
Advertising	455	531
Telephone	1,149	1,606
Computer costs	1,878	378
Travelling and Subsistence	173	695
Bank charges	23	133
General expenses	705	2,965
Auditor's remuneration	2,000	1,930
	<u>111,992</u>	<u>112,643</u>
Net surplus	<u>2,296</u>	<u>1,645</u>

Note 1 : €3,000 costed to this account was refunded in 2017 and will be spent then.

Note 2 : €8,000 of this Research cost will be spent in 2017

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

INCOME STATEMENT

for the year ended 31 December 2016

CL 2-9

	Notes	2016 €	2015 €
Income		138,097	137,797
Expenditure		(137,785)	(138,378)
Surplus/(deficit) for the year		<u>312</u>	<u>(581)</u>

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

DETAILED INCOME AND EXPENDITURE ACCOUNT

for the year ended 31 December 2016

CL 2-9

	2016 €	2015 €
Income		
Education and Training Income	138,097	137,797
	<u>138,097</u>	<u>137,797</u>
Expenditure		
Programme Costs	6,911	14,467
Training	400	-
Facilitation	1,500	(75)
Wages and salaries	102,123	97,958
Social welfare costs	10,978	10,530
Supervision	-	930
Rent payable	5,112	5,224
Light and heat	824	589
Repairs and maintenance	1,046	710
Printing, postage and stationery	2,279	2,162
Advertising	473	401
Telephone	1,811	1,796
Computer costs	1,071	411
Main Reallocation	-	10
Travelling and Subsistence	672	1,386
Bank charges	30	10
General expenses	1,432	999
Auditor's remuneration	1,123	870
	<u>137,785</u>	<u>138,378</u>
Net surplus/(deficit)	<u>312</u>	<u>(581)</u>

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

INCOME STATEMENT

for the year ended 31 December 2016

Main

	Notes	2016 €	2015 €
Income		-	10
Expenditure		(27)	(14)
Deficit for the year		(27)	(4)

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

DETAILED INCOME AND EXPENDITURE ACCOUNT

for the year ended 31 December 2016

Main

	2016 €	2015 €
Income		
CL 2-9 Reallocation	-	10
	<u>-</u>	<u>10</u>
	-	10
	<u>-</u>	<u>10</u>
Expenditure		
Bank charges	27	14
	<u>27</u>	<u>14</u>
	27	14
	<u>27</u>	<u>14</u>
Net deficit	<u>(27)</u>	<u>(4)</u>

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

INCOME STATEMENT

for the year ended 31 December 2016

Pobal

	Notes	2016 €	2015 €
Income		-	30,139
Expenditure		-	(30,139)
Surplus for the year		-	-

Clondalkin Drug and Alcohol Task Force Project Management CLG

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

DETAILED INCOME AND EXPENDITURE ACCOUNT

for the year ended 31 December 2016

Pobal

	2016 €	2015 €
Income		
Pobal Income	-	30,139
	<hr/>	<hr/>
	-	30,139
	<hr/>	<hr/>
Expenditure		
2016 Deferred Expenditure	-	30,139
	<hr/>	<hr/>
	-	30,139
	<hr/>	<hr/>
Net surplus	-	-
	<hr/>	<hr/>